Search - tctmd.com

Displaying 261 - 280 of 658

Sort: Relevancy | Date

When Is It Time to Abandon Thrombectomy for Acute Stroke? New Clues

News Daily News

When Is It Time to Abandon Thrombectomy for Acute Stroke? New Clues

February 25, 2019

Window for IV Thrombolysis in Stroke May Stay Open Twice as Long With Imaging Selection

News Conference News ISC 2019

Window for IV Thrombolysis in Stroke May Stay Open Twice as Long With Imaging Selection

February 14, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Mechanical Thrombectomy Outcomes May Be Worse at Low-Volume Stroke Centers

News Conference News ISC 2019

Mechanical Thrombectomy Outcomes May Be Worse at Low-Volume Stroke Centers

February 07, 2019

Working Less, Earning Less: Stroke, MI, and Cardiac Arrest Have Long-term Labor Consequences

News Daily News

Working Less, Earning Less: Stroke, MI, and Cardiac Arrest Have Long-term Labor Consequences

Michael O'Riordan

January 07, 2019

Many PCI Patients Treated in China Have No Angina Symptoms

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

December 20, 2018

Man’s Best Friend, Especially After an MI or Stroke

News Conference News WCC 2018

Man’s Best Friend, Especially After an MI or Stroke

December 11, 2018

Manuscript

Clinical and Economic Burden of Acute Ischemic Stroke Following Transcatheter Aortic Valve Replacement

December 11, 2018

NICE Revisits UK Stroke Guidance, Including Thrombectomy

News Daily News

NICE Revisits UK Stroke Guidance, Including Thrombectomy

November 30, 2018

Complications Following TAVR Are Going Down, US Data Show

News Conference News AHA 2018

Complications Following TAVR Are Going Down, US Data Show

Yael L. Maxwell

November 20, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Study Lays Groundwork for Pivotal Trial of Impella CP for LV Unloading Before PCI

News Conference News AHA 2018

Study Lays Groundwork for Pivotal Trial of Impella CP for LV Unloading Before PCI

November 11, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

New BMJ Guidance Urges Prudence With Supplemental Oxygen, Especially in Acute MI, Stroke

News Daily News

New BMJ Guidance Urges Prudence With Supplemental Oxygen, Especially in Acute MI, Stroke

Yael L. Maxwell

October 25, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Hospital Readmissions at 30 Days Declining for Stroke Patients

News Daily News

Hospital Readmissions at 30 Days Declining for Stroke Patients

Michael O'Riordan

August 20, 2018

IV Alteplase No Help for Minor, Nondisabling Strokes in PRISMS Trial

News Daily News

IV Alteplase No Help for Minor, Nondisabling Strokes in PRISMS Trial

July 11, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.